Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Neuroregulatory proteins (NRGs) are a family of growth factors with multiple effects and play an important role in many neurological disorders (including multiple sclerosis, brain trauma, spinal cord injury, peripheral neuropathy, and schizophrenia). There are four kinds of NRRG genes in mammals, which are coded as NRG1, NRG2, NRG3 and NRG4, respectively. NRG originated from the isolation and extraction of nerve tissue, because it can promote the proliferation of Schwann cells in the nervous system, also known as glial growth factor. Among them, the research of NRG1 is the most extensive. The NRG1 gene is located on chromosome 8 of humans and mice and can encode 21 kinds of exons. By selective splicing and different promoters, at least 31 subtypes including secreted and cross-model can be generated. NRG1 has a wide range of roles in the development of the nervous system, heart, and breast. It can regulate synaptic plasticity, stimulate proliferation and survival, and regulate the activity of many different cell types.
Figure 1. Schematic of BACE1-dependent NRG1/ErbB4 signaling pathway involving in the pathogenies of schizophrenia. (Zhengrong, Z., et al. 2017)
NRG1 subtypes all contain an EGF-like signaling domain, which is indispensable for regulating biological activity. NRG1 needs to bind to the dimerization receptor to transmit signals. First, the EGF-like domain is bound to the tyrosine kinase receptor ErbB3 or ErbB4. ErbB3 or ErbB4 then forms a heterodimer with ErbB2. ErbB2 lacks a ligand-binding domain, so it acts as a co-receptor in signal transduction, while ErbB3 lacks an activated tyrosine kinase domain, and must bind to ErbB2 for signal transduction. In the peripheral nervous system, NRG1/ErbB is a key regulator of the axon-Schwann cell connection and can regulate Schwann cell development. NRG1 can induce neural crest cells to differentiate, proliferate, and migrate to Schwann cells, and promote the survival of embryonic Schwann cell precursor cells and immature Schwann cells, which is necessary for the normal formation and sensory function of myelin sheath. In the central nervous system, NRG1 promotes the proliferation of microglia and participates in the formation and development of neuropathic pain by binding to the ErbB2 receptor on the microglia membrane of the dorsal horn of the spinal cord.
The study found that only intrathecal injection of NRG1-β1 protein in rats can significantly reduce the tactile withdrawal threshold of the hind paws of rats, resulting in transient touch-induced pain. The study found that excluding schizophrenia-related gene NRG1 reduced the sensitivity to heat pain in mice, suggesting that the NRG1 gene may be closely related to pain and heat perception abnormalities in patients with schizophrenia. In a mixed bone cancer pain model of neuropathic pain and inflammatory pain, it was found that 3 weeks after injection of tumor cells, time-dependent levels of NRG1, ErbB2, and phosphorylated ErbB2 increased, and exogenous NRG1 was administered intrathecally. Up-regulation of ErbB2 and phosphorylated ErbB2 messenger RNA and protein levels produce thermal hyperalgesia and mechanical hyperalgesia, while ErbB2 signaling inhibitors greatly reduce thermal hyperalgesia and mechanical hyperalgesia in cancerous bone pain. In a phase II clinical trial, it was found that the ErbB2 inhibitor lapatinib used for breast cancer treatment can improve the symptoms and reduce pain at the same time. Further research found that in the model of facial nerve injury, ErbB3 levels and mechanical touch sensation increased synchronously with time, and lapatinib could significantly reduce mechanical touch evoked pain in a dose-dependent manner.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.